Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V L Sharman

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|November 1, 1983
Hydralazine and prazosin in the treatment of hypertensionM J Vandenburg, V L Sharman, P Wright, et al.
European Journal of Clinical Pharmacology|January 1, 1983
The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertensionM J Vandenburg, J M Holly, F J Goodwin, et al.
Postgraduate Medical Journal|May 1, 1981
Hormonal and blood pressure changes during converting enzyme inhibition by teprotideM J VandenBurg, V L Sharman, J J Morton, et al.
Annals of the Rheumatic Diseases|August 1, 1981
Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placeboJ Woodland, D M Chaput de Saintonge, S J Evans, et al.
British Journal of Clinical Pharmacology|March 1, 1984
Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tiltingD R Turner, F J Goodwin, A R Knight, et al.
British Medical Journal (Clinical Research Ed.)|July 10, 1982
Do patients receiving regular haemodialysis need folic acid supplements?V L Sharman, J Cunningham, F J Goodwin, et al.
Lancet (London, England)|October 12, 1985
Azathioprine and cyclosporin: different tissue matching criteria needed?K R Harris, N Digard, D C Gosling, et al.
The Quarterly Journal of Medicine|January 1, 1982
Long-term experience of alfacalcidol in renal osteodystrophyV L Sharman, A M Brownjohn, F J Goodwin, et al.
Clinical Nephrology|October 1, 1986
Controlled trial of calcitriol in hemodialysis patientsL R Baker, J W Muir, V L Sharman, et al.
Contributions to Nephrology|January 1, 1980
Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observationsL R Baker, J W Muir, W R Cattell, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|November 1, 1983
Hydralazine and prazosin in the treatment of hypertensionM J Vandenburg, V L Sharman, P Wright, et al.
European Journal of Clinical Pharmacology|January 1, 1983
The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertensionM J Vandenburg, J M Holly, F J Goodwin, et al.
Postgraduate Medical Journal|May 1, 1981
Hormonal and blood pressure changes during converting enzyme inhibition by teprotideM J VandenBurg, V L Sharman, J J Morton, et al.
Annals of the Rheumatic Diseases|August 1, 1981
Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placeboJ Woodland, D M Chaput de Saintonge, S J Evans, et al.
British Journal of Clinical Pharmacology|March 1, 1984
Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tiltingD R Turner, F J Goodwin, A R Knight, et al.
British Medical Journal (Clinical Research Ed.)|July 10, 1982
Do patients receiving regular haemodialysis need folic acid supplements?V L Sharman, J Cunningham, F J Goodwin, et al.
Lancet (London, England)|October 12, 1985
Azathioprine and cyclosporin: different tissue matching criteria needed?K R Harris, N Digard, D C Gosling, et al.
The Quarterly Journal of Medicine|January 1, 1982
Long-term experience of alfacalcidol in renal osteodystrophyV L Sharman, A M Brownjohn, F J Goodwin, et al.
Clinical Nephrology|October 1, 1986
Controlled trial of calcitriol in hemodialysis patientsL R Baker, J W Muir, V L Sharman, et al.
Contributions to Nephrology|January 1, 1980
Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observationsL R Baker, J W Muir, W R Cattell, et al.
Pageof 3